Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-Time-in-Human Phase 1/2 Study of GSK5471713 in Adults With Metastatic Castration-Resistant Prostate Cancer
jRCT2031250732Phase 2Recruiting
- Sponsor
- GSK
- Start
- Mar 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of GSK5471713 in castration-resistant prostate cancer (CRPC), sponsored by GSK. Primary endpoints: Number of participants with dose limiting toxicities (DLTs), Number of participants with adverse events (AEs) and serious adverse events (SAEs) and 2 more. Started Mar 2026; status: recruiting.
02
Drugs
GSK5471713
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on jRCT2031250732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250732.